Boltz

Boltz is an artificial intelligence research company and Public Benefit Corporation (PBC) focused on developing foundation models for biomolecular design and drug discovery. Founded by a team from MIT, the company provides open-source and enterprise-grade tools that predict the 3D structure of biological complexes and their binding affinities with state-of-the-art accuracy. Boltz operates the Boltz Lab platform, a software-as-a-service suite that integrates generative AI agents into scientific workflows for small-molecule and protein design. In early 2026, the company entered a high-profile strategic collaboration with Pfizer to deploy custom AI foundation models across Pfizer’s global research organization. Unlike traditional therapeutic biotechs, Boltz positions itself as an infrastructure provider, offering the computational tools necessary to eliminate early-stage drug discovery bottlenecks.